These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35833618)

  • 1. "Now at least we have something to call it": Patient and care partner experiences receiving an amyloid PET scan.
    Gadbois EA; Bélanger E; Shield RR; Plassman BL; Van Houtven CH; Wetle TF
    J Am Geriatr Soc; 2022 Oct; 70(10):2938-2947. PubMed ID: 35833618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?
    James HJ; Van Houtven CH; Lippmann S; Burke JR; Shepherd-Banigan M; Belanger E; Wetle TF; Plassman BL
    J Alzheimers Dis; 2020; 74(2):625-636. PubMed ID: 32065790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactions to Amyloid PET Scan Results and Levels of Anxious and Depressive Symptoms: CARE IDEAS Study.
    Bélanger E; D'Silva J; Carroll MS; Van Houtven CH; Shepherd-Banigan M; Smith VA; Wetle TT
    Gerontologist; 2023 Jan; 63(1):71-81. PubMed ID: 35436334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advance directives among cognitively impaired persons who had an amyloid PET scan and their care partners: a mixed-methods study.
    Bélanger E; Couch E; Carroll MS; DePasquale N; Gadbois EA; Shepherd-Banigan M; Jutkowitz E; Van Houtven CH; Plassman BL; Wetle TT
    BMC Palliat Care; 2022 Nov; 21(1):194. PubMed ID: 36336690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "I know that my role is going to change": a mixed-methods study of the relationship between amyloid-β PET scan results and caregiver burden.
    Couch E; Belanger E; Gadbois EA; DePasquale N; Zhang W; Wetle T
    Aging Clin Exp Res; 2023 Feb; 35(2):387-397. PubMed ID: 36484946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    Shepherd-Banigan ME; Ford CB; Smith VA; Belanger E; Wetle TT; Plassman BL; Burke JR; DePasquale N; O'Brien EC; Sorenson C; Van Houtven CH
    J Alzheimers Dis; 2022; 90(2):775-782. PubMed ID: 36189596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to Undergo a Risky Treatment to Improve Cognition Among Persons With Cognitive Impairment Who Received an Amyloid PET Scan.
    Jutkowitz E; Van Houtven CH; Plassman BL; Mor V
    Alzheimer Dis Assoc Disord; 2020; 34(1):1-9. PubMed ID: 31414990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.
    Iaccarino L; La Joie R; Lesman-Segev OH; Lee E; Hanna L; Allen IE; Hillner BE; Siegel BA; Whitmer RA; Carrillo MC; Gatsonis C; Rabinovici GD
    JAMA Neurol; 2021 Feb; 78(2):197-207. PubMed ID: 33252608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
    Boccardi M; Altomare D; Ferrari C; Festari C; Guerra UP; Paghera B; Pizzocaro C; Lussignoli G; Geroldi C; Zanetti O; Cotelli MS; Turla M; Borroni B; Rozzini L; Mirabile D; Defanti C; Gennuso M; Prelle A; Gentile S; Morandi A; Vollaro S; Volta GD; Bianchetti A; Conti MZ; Cappuccio M; Carbone P; Bellandi D; Abruzzi L; Bettoni L; Villani D; Raimondi MC; Lanari A; Ciccone A; Facchi E; Di Fazio I; Rozzini R; Boffelli S; Manzoni L; Salvi GP; Cavaliere S; Belotti G; Avanzi S; Pasqualetti P; Muscio C; Padovani A; Frisoni GB;
    JAMA Neurol; 2016 Dec; 73(12):1417-1424. PubMed ID: 27802513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study.
    O'Brien EC; Ford CB; Sorenson C; Jutkowitz E; Shepherd-Banigan M; Van Houtven C
    Alzheimers Res Ther; 2023 Jan; 15(1):6. PubMed ID: 36611213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline.
    Sarkis RA; Gale SA; Yang HS; Lam AD; Singhal T; Cicero S; Willment K; McGinnis SM
    Am J Alzheimers Dis Other Demen; 2023; 38():15333175231160005. PubMed ID: 36892007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and caregiver reactions to clinical amyloid imaging.
    Grill JD; Cox CG; Kremen S; Mendez MF; Teng E; Shapira J; Ringman JM; Apostolova LG
    Alzheimers Dement; 2017 Aug; 13(8):924-932. PubMed ID: 28174068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement Properties of the CAPACITY Instrument to Assess Perceived Communication With the Health Care Team Among Care Partners of Patients With Cognitive Impairment.
    Van Houtven CH; Lippmann SJ; Bélanger E; Smith VA; James HJ; Shepherd-Banigan M; Jutkowitz E; O'Brien E; Wolff JL; Burke JR; Plassman BL
    Med Care; 2020 Sep; 58(9):842-849. PubMed ID: 32826749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.